

November is National Pet Cancer Awareness Month. One of the most common questions pet owners ask when their favorite fur person is diagnosed with cancer is, “How did he get this kind of cancer?” Most of the time, we don’t have a clear answer. But new research into the feline oncogenome—the genetic makeup of a cat’s tumor—is helping us understand the changes involved in feline cancer.
What is an oncogenome?
An oncogenome is the genetic makeup of a tumor. Onco- is derived from the Greek word ónkos, meaning “bulk,” “mass,” or “tumor”. This explains why a cancer specialist is called an oncologist and a cancer-causing virus is an oncovirus. Genome may be more familiar: it is your genetic code held in your DNA and its associated proteins.
Studying the Feline Oncogenome
In the study published in Science, veterinary scientists studied tumors from almost 500 cats. These cats were typical of the ones I see in my oncology clinic: older, with an average age of 11, and mostly not purebred—83% were mixed breed. What was a bit more unusual: 56% were female. There is a good explanation for that imbalance. All the breast cancer cases in the study were in female cats.
To study an oncogenome, you need cancer tissue. The researchers examined 13 types of feline tumors, including lymphoma, breast cancer, bone cancer (osteosarcoma), mast cell tumors, lung cancer and oral squamous cell carcinoma.
The scientists extracted DNA from tumor tissue and normal tissue, then compared them. They also screened the feline oncogenomes for 900 different genes known to be associated with cancer in humans. The goal: find genetic changes that might help explain how these tumors develop.
Which gene mutations were found in feline cancer?
The most frequently mutated gene was TP53, with mutations found in about one-third of the cats studied—a frequency similar to that seen in human cancers. Normally, TP53 helps protect against cancer. Mutations can interfere with that protection. Elephants have many copies of this gene, which may help explain their low rates of cancer, as I’ve written about before.
Another familiar gene turned up: KIT, which was mutated in nearly half of the feline cutaneous mast cell tumors. We see KIT mutations in canine mast cell tumors, too. KIT is a target of a cancer drug for dogs that veterinarians also prescribe for some cats with mast cell tumors. This finding adds to the rationale for targeting KIT.
What does this research mean for my cat’s cancer treatment?
These results help veterinarians understand the genetic mutations that underlie feline cancer. Since many of the mutations occur in human cancers as well, we hope this information will help veterinary oncologists adapt human treatments and fine new treatments for feline cancer. Right now, the results don’t help us treat cancer in cats, but these results are critical to ongoing investigations that our feline companions desperately need—and that is welcome news.
Tags:
cancer, cancer in cats, cats, feline cancer, feline genetics, feline oncogenome, feline research, genetics, oncogenome, research,